Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 4%

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report)'s stock price traded up 4% on Thursday . The company traded as high as $14.40 and last traded at $14.34. 24,526 shares were traded during trading, a decline of 94% from the average session volume of 401,357 shares. The stock had previously closed at $13.79.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Wedbush restated an "outperform" rating and set a $18.00 target price (up from $12.00) on shares of Y-mAbs Therapeutics in a report on Monday, February 12th. HC Wainwright boosted their price target on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a report on Wednesday, March 6th. BMO Capital Markets boosted their price target on shares of Y-mAbs Therapeutics from $16.00 to $26.00 and gave the company an "outperform" rating in a report on Monday, March 4th. Finally, Canaccord Genuity Group boosted their price target on shares of Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a "buy" rating in a report on Monday, March 4th. Two research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $16.57.

Y-mAbs Therapeutics Stock Performance

The firm's 50 day moving average is $15.58 and its 200-day moving average is $9.77. The firm has a market cap of $640.46 million, a price-to-earnings ratio of -29.86 and a beta of 0.74.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its quarterly earnings data on Thursday, February 29th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.17. Y-mAbs Therapeutics had a negative net margin of 25.26% and a negative return on equity of 20.72%. The business had revenue of $23.36 million during the quarter, compared to analyst estimates of $21.72 million. As a group, research analysts predict that Y-mAbs Therapeutics, Inc. will post -0.43 EPS for the current year.

Insider Activity at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, SVP Vignesh Rajah sold 1,711 shares of the business's stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $16.53, for a total transaction of $28,282.83. Following the completion of the transaction, the senior vice president now owns 33,889 shares of the company's stock, valued at approximately $560,185.17. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 21.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Trexquant Investment LP lifted its position in Y-mAbs Therapeutics by 417.5% during the 3rd quarter. Trexquant Investment LP now owns 76,585 shares of the company's stock worth $417,000 after acquiring an additional 61,785 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Y-mAbs Therapeutics by 24.0% during the third quarter. Acadian Asset Management LLC now owns 811,261 shares of the company's stock valued at $4,420,000 after buying an additional 157,173 shares during the last quarter. GSA Capital Partners LLP raised its position in shares of Y-mAbs Therapeutics by 208.3% during the third quarter. GSA Capital Partners LLP now owns 137,299 shares of the company's stock valued at $748,000 after buying an additional 92,765 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Y-mAbs Therapeutics during the fourth quarter valued at about $34,000. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Y-mAbs Therapeutics by 258.2% during the third quarter. Massachusetts Financial Services Co. MA now owns 82,131 shares of the company's stock valued at $448,000 after buying an additional 59,201 shares during the last quarter. Institutional investors and hedge funds own 70.85% of the company's stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.